ResearcherUniversity of FreiburgActive in the last 2 years
Saskia Hussung
Matched on ORCID iD 0000-0001-7987-0065; OpenAlex author ID A5073108388. Sources: OpenAlex.
Their work
- Papers
- 14 (first author 3, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 42
2017: 2 papers · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 5 papers · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers
Papers 14
- A stratified two-stage tumor molecular profiling algorithm to identify clinically actionable molecular alterations in pancreatic cancer. Co-author DOI 10.1016/j.esmogo.2025.100134↗
- Real-World Advances in Metastatic Pancreatic Cancer Treatment in the Pre-Molecular Era: A Retrospective Single-Center Analysis 2010-2018. First author DOI 10.1159/000546307↗
- Ex vivo modeling of acquired drug resistance in BRAF - mutated pancreatic cancer organoids uncovers individual therapeutic vulnerabilities. Co-author DOI 10.1016/j.canlet.2024.216650↗
- Integrated Analysis of Cell-Free DNA and Novel Protein Biomarkers for Stratification and Therapy Monitoring in Stage IV Pancreatic Cancer: A Preliminary Study. Co-author DOI 10.3390/diagnostics15010049↗
- Is Computed-Tomography-Based Body Composition a Reliable Predictor of Chemotherapy-Related Toxicity in Pancreatic Cancer Patients? Co-author DOI 10.3390/cancers15174398↗
- Plasma biomarkers for prediction of early tumor recurrence after resection of pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41598-021-86779-x↗
- Perioperative cell-free mutant KRAS dynamics in patients with pancreatic cancer First author DOI 10.1093/bjs/znaa116↗
- Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled Trials. Co-author DOI 10.1097/sla.0000000000005126↗
- Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer. Co-author DOI 10.1186/s12885-020-07736-x↗
- β6-Integrin Serves as a Potential Serum Marker for Diagnosis and Prognosis of Pancreatic Adenocarcinoma. Co-author DOI 10.14309/ctg.0000000000000395↗
- Metabolic Profiling of Early and Late Recurrent Pancreatic Ductal Adenocarcinoma Using Patient-Derived Organoid Cultures. Co-author DOI 10.3390/cancers12061440↗
- Identification and Validation of a Diagnostic and Prognostic Multi-Gene Biomarker Panel for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fgene.2018.00108↗
- Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations. Co-author DOI 10.1038/s41598-017-04601-z↗
- Author Correction: Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations. Co-author DOI 10.1038/s41598-017-14870-3↗
Closest collaborators
The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ralph Fritsch · 14 shared papers, 2017–2025 · strength 2.14
- Paper Real-World Advances in Metastatic Pancreatic Cancer Treatment in the Pre-Molecular Era: A Retrospective Single-Center A… DOI 10.1159/000546307↗
- Paper Integrated Analysis of Cell-Free DNA and Novel Protein Biomarkers for Stratification and Therapy Monitoring in Stage IV… DOI 10.3390/diagnostics15010049↗
- Paper A stratified two-stage tumor molecular profiling algorithm to identify clinically actionable molecular alterations in p… DOI 10.1016/j.esmogo.2025.100134↗
- Uwe A. Wittel · 6 shared papers, 2018–2024 · strength 0.85
- Paper Integrated Analysis of Cell-Free DNA and Novel Protein Biomarkers for Stratification and Therapy Monitoring in Stage IV… DOI 10.3390/diagnostics15010049↗
- Paper Perioperative cell-free mutant KRAS dynamics in patients with pancreatic cancer DOI 10.1093/bjs/znaa116↗
- Paper Plasma biomarkers for prediction of early tumor recurrence after resection of pancreatic ductal adenocarcinoma. DOI 10.1038/s41598-021-86779-x↗
- Melanie Boerries · 4 shared papers, 2018–2024 · strength 0.59
- Paper Integrated Analysis of Cell-Free DNA and Novel Protein Biomarkers for Stratification and Therapy Monitoring in Stage IV… DOI 10.3390/diagnostics15010049↗
- Paper Perioperative cell-free mutant KRAS dynamics in patients with pancreatic cancer DOI 10.1093/bjs/znaa116↗
- Paper Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreati… DOI 10.1186/s12885-020-07736-x↗
- Daniela M. Lenggenhager · 3 shared papers, 2021–2025 · strength 0.55
- Paper A stratified two-stage tumor molecular profiling algorithm to identify clinically actionable molecular alterations in p… DOI 10.1016/j.esmogo.2025.100134↗
- Paper Ex vivo modeling of acquired drug resistance in BRAF - mutated pancreatic cancer organoids uncovers individual therapeu… DOI 10.1016/j.canlet.2024.216650↗
- Paper β6-Integrin Serves as a Potential Serum Marker for Diagnosis and Prognosis of Pancreatic Adenocarcinoma. DOI 10.14309/ctg.0000000000000395↗
- Chantal Pauli · 2 shared papers, 2024–2025 · strength 0.43
- Paper A stratified two-stage tumor molecular profiling algorithm to identify clinically actionable molecular alterations in p… DOI 10.1016/j.esmogo.2025.100134↗
- Paper Ex vivo modeling of acquired drug resistance in BRAF - mutated pancreatic cancer organoids uncovers individual therapeu… DOI 10.1016/j.canlet.2024.216650↗
- Anina Julia Ruth Mäder · 1 shared paper, 2025 · strength 0.37
- Julian Hipp · 2 shared papers, 2021 · strength 0.26
- Lukas M. Braun · 2 shared papers, 2020–2021 · strength 0.26
- Paper Plasma biomarkers for prediction of early tumor recurrence after resection of pancreatic ductal adenocarcinoma. DOI 10.1038/s41598-021-86779-x↗
- Paper Metabolic Profiling of Early and Late Recurrent Pancreatic Ductal Adenocarcinoma Using Patient-Derived Organoid Culture… DOI 10.3390/cancers12061440↗
- Sabrina Steiner · 1 shared paper, 2024 · strength 0.21
- Sara De Dosso · 1 shared paper, 2023 · strength 0.16
- Dieter Koeberle · 1 shared paper, 2023 · strength 0.16
- Stefania Rizzo · 1 shared paper, 2023 · strength 0.16
- Marco Cefalì · 1 shared paper, 2023 · strength 0.16
- Filippo Del Grande · 1 shared paper, 2023 · strength 0.16
- Sylvia Timme‐Bronsert · 1 shared paper, 2021 · strength 0.14
- Marie-Claire Rittmann · 1 shared paper, 2021 · strength 0.13
- Dietrich Alexander Ruess · 1 shared paper, 2021 · strength 0.13
- Bernd Kammerer · 1 shared paper, 2020 · strength 0.13
- Simon Lagies · 1 shared paper, 2020 · strength 0.13
- Bernhard Kaspar Morell · 1 shared paper, 2021 · strength 0.12
- Verena Martini · 2 shared papers, 2017 · strength 0.12
- Sylvia Timme · 2 shared papers, 2017 · strength 0.12
- Martha B. Pitman · 2 shared papers, 2017 · strength 0.12
- Heiko Becker · 2 shared papers, 2017 · strength 0.12
- Birte Kulemann · 2 shared papers, 2017 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.